Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GLYC Stock Forecast 2025-2026
$14.62
Current Price
$10.13M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GLYC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
GLYC Price Momentum
-14.0%
1 Week Change
-43.8%
1 Month Change
-39.1%
1 Year Change
-41.5%
Year-to-Date Change
-76.8%
From 52W High of $63.00
+32.2%
From 52W Low of $11.06
📊 TOP ANALYST CALLS
Did GLYC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GlycoMimetics is one of their latest high-conviction picks.
Latest GLYC Stock Price Targets & Analyst Predictions
GLYC has shown a year-to-date change of -41.5% and a 1-year change of -39.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GLYC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLYC Analyst Ratings
1
Buy
0
Hold
0
Sell
GLYC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $14.62
Latest GLYC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLYC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $0.00 |
| Jul 26, 2024 | TD Cowen | Boris Peaker | Hold | Downgrade | $0.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| May 6, 2024 | HC Wainwright & Co. | Edward White | Neutral | Downgrade | $0.00 |
| Mar 27, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $8.00 |
| Dec 22, 2023 | Capital One | Zegbeh Jallah | Overweight | Initiates | $12.00 |
| Aug 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Jun 15, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| May 4, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Mar 30, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Feb 16, 2023 | HC Wainwright & Co. | Edward White | Buy | Maintains | $8.00 |
| Aug 4, 2022 | HC Wainwright & Co. | Edward White | Buy | Maintains | $13.00 |
| Nov 12, 2021 | Jefferies | Roger Song | Buy | Upgrade | $4.00 |
| Dec 8, 2020 | Roth Capital | Buy | Maintains | $15.00 | |
| Jul 31, 2020 | HC Wainwright & Co. | Buy | Maintains | $15.00 | |
| Mar 2, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Mar 2, 2020 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $16.00 |
| Nov 14, 2019 | Roth Capital | Buy | Initiates | $0.00 | |
| Aug 5, 2019 | Piper Jaffray | Neutral | Downgrade | $0.00 | |
| Aug 5, 2019 | Jefferies | Hold | Downgrade | $0.00 |
GlycoMimetics Inc. (GLYC) Competitors
The following stocks are similar to GlycoMimetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GlycoMimetics Inc. (GLYC) Financial Data
GlycoMimetics Inc. has a market capitalization of $10.13M with a P/E ratio of -24.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -182.7%.
Valuation Metrics
Market Cap
$10.13M
Enterprise Value
$4.58M
P/E Ratio
-24.8x
PEG Ratio
-1.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+59.5%
Current Ratio
2.3x
Debt/Equity
0.0x
ROE
-182.7%
ROA
-74.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
GlycoMimetics Inc. (GLYC) Business Model
About GlycoMimetics Inc.
What They Do
Develops innovative glycomimetic drugs for diseases.
Business Model
GlycoMimetics Inc. generates revenue through the discovery and development of glycomimetic drugs aimed at treating oncology and inflammatory diseases. The company collaborates with industry partners and research institutions to leverage technology and expand clinical trials, which helps in bringing their products to market.
Additional Information
The company's pipeline includes treatments for acute myeloid leukemia and other hematologic disorders, addressing significant unmet medical needs. Operating within the dynamic pharmaceutical industry, GlycoMimetics is focused on enhancing therapeutic outcomes amidst rising global health challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Harout Semerjian
Country
United States
IPO Year
2014
Website
www.glycomimetics.comGlycoMimetics Inc. (GLYC) Latest News & Analysis
Latest News
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
14 days ago
Quick Summary
GlycoMimetics, Inc. announced stockholder approval for its merger with Crescent Biopharma, including a reverse stock split, at a special meeting held on June 5, 2025.
Why It Matters
The merger approval and reverse stock split could impact GlycoMimetics' stock liquidity and valuation, influencing market perception and investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Crescent Biopharma will present at the Jefferies Global Healthcare Conference on June 5, 2025, showcasing its precision-engineered molecules for solid tumors.
Why It Matters
Crescent Biopharma's presentation at a major healthcare conference could attract investor interest, signal potential breakthroughs in oncology, and impact stock valuations in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the merger between GlycoMimetics, Inc. and Crescent Biopharma, Inc. for shareholder fairness.
Why It Matters
The investigation into GlycoMimetics' merger raises concerns about shareholder value and the fairness of the deal, potentially impacting stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Crescent Biopharma appointed David Lubner, a finance and operations veteran with 30 years of experience, to its board of directors to enhance its strategic direction.
Why It Matters
David Lubner's appointment enhances Crescent Biopharma's leadership, potentially boosting investor confidence in its strategic direction and operational expertise, impacting future growth and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Jonathan McNeill, M.D., has been appointed as President and Chief Operating Officer, succeeding Ellie Im, M.D.
Why It Matters
Leadership changes can impact company strategy and performance, influencing investor confidence and stock prices. McNeill's appointment may signal a shift in operational direction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
3 months ago
Quick Summary
Halper Sadeh LLC is investigating Chimerix, Inc. for potential violations related to its sale to Jazz Pharmaceuticals for $8.55 per share. Shareholders may have rights and options.
Why It Matters
The investigation into Chimerix's sale may indicate potential legal issues that could affect the deal's completion or stock value, raising concerns for shareholders and impacting investment decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GLYC Stock
What is GlycoMimetics Inc.'s (GLYC) stock forecast for 2025?
Analyst forecasts for GlycoMimetics Inc. (GLYC) are not currently available. The stock is trading at $14.62.
Is GLYC stock a good investment in 2025?
According to current analyst ratings, GLYC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GLYC stock?
Price predictions from Wall Street analysts for GLYC are not currently available. The stock is trading at $14.62.
What is GlycoMimetics Inc.'s business model?
GlycoMimetics Inc. generates revenue through the discovery and development of glycomimetic drugs aimed at treating oncology and inflammatory diseases. The company collaborates with industry partners and research institutions to leverage technology and expand clinical trials, which helps in bringing their products to market.
What is the highest forecasted price for GLYC GlycoMimetics Inc.?
Price targets from Wall Street analysts for GLYC are not currently available. The stock is trading at $14.62.
What is the lowest forecasted price for GLYC GlycoMimetics Inc.?
Price targets from Wall Street analysts for GLYC are not currently available. The stock is trading at $14.62.
What is the overall GLYC consensus from analysts for GlycoMimetics Inc.?
The overall analyst consensus for GLYC is bullish. Out of 7 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are GLYC stock price projections?
Stock price projections, including those for GlycoMimetics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 9:44 PM UTC